Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · IEX Real-Time Price · USD
76.12
+0.71 (0.94%)
At close: Jul 2, 2024, 4:00 PM
76.08
-0.04 (-0.05%)
After-hours: Jul 2, 2024, 7:49 PM EDT
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2024, Dr. Reddy's Laboratories had annual revenue of $3.35B with 11.97% growth.
Revenue (ttm)
$3.35B
Revenue Growth
+11.97%
P/S Ratio
3.78
Revenue / Employee
$129,502
Employees
25,863
Market Cap
12.68B USD
Revenue Chart
* The company reports in INR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 3.35B | 358.07M | 11.97% |
Mar 31, 2023 | 2.99B | 177.70M | 6.32% |
Mar 31, 2022 | 2.81B | 228.76M | 8.85% |
Mar 31, 2021 | 2.58B | 269.12M | 11.62% |
Mar 31, 2020 | 2.32B | 92.37M | 4.15% |
Mar 31, 2019 | 2.22B | 41.59M | 1.91% |
Mar 31, 2018 | 2.18B | 13.23M | 0.61% |
Mar 31, 2017 | 2.17B | -165.41M | -7.09% |
Mar 31, 2016 | 2.33B | -33.74M | -1.42% |
Mar 31, 2015 | 2.37B | 159.80M | 7.24% |
Mar 31, 2014 | 2.21B | 67.36M | 3.15% |
Mar 31, 2013 | 2.14B | 232.69M | 12.20% |
Mar 31, 2012 | 1.91B | 231.71M | 13.82% |
Mar 31, 2011 | 1.68B | 111.29M | 7.11% |
Mar 31, 2010 | 1.56B | 196.93M | 14.40% |
Mar 31, 2009 | 1.37B | 118.18M | 9.46% |
Mar 31, 2008 | 1.25B | -252.03M | -16.78% |
Mar 31, 2007 | 1.50B | 956.82M | 175.61% |
Mar 31, 2006 | 544.85M | 97.83M | 21.89% |
Mar 31, 2005 | 447.02M | -16.09M | -3.47% |
Mar 31, 2004 | 463.11M | 83.73M | 22.07% |
Mar 31, 2003 | 379.39M | 38.58M | 11.32% |
Mar 31, 2002 | 340.80M | 104.68M | 44.33% |
Mar 31, 2001 | 236.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fresenius Medical Care AG & Co. KGaA | 21.17B |
Tenet Healthcare | 20.91B |
Viatris | 15.36B |
DaVita | 12.34B |
Incyte | 3.77B |
Revvity | 2.73B |
Royalty Pharma | 2.24B |
Medpace Holdings | 1.96B |
RDY News
- 6 days ago - Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business - Business Wire
- 4 weeks ago - Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities - Business Wire
- 5 weeks ago - Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America - Business Wire
- 6 weeks ago - Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK - Business Wire
- 2 months ago - Dr. Reddy's Q4 & Full Year FY24 Financial Results - Business Wire
- 2 months ago - Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S. - Business Wire
- 3 months ago - Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK - Business Wire
- 5 months ago - Dr. Reddy's Q3 & 9M FY24 Financial Results - Business Wire